课题基金 / 基金详情

Addressing pharmacy practice in low and middle income settings in an era of antibiotic resistance

Addressing pharmacy practice in low and middle income settings in an era of antibiotic resistance
解决抗生素耐药性时代中低收入环境的药学实践
批准号:
ES/T006854/1
负责人:
Rosalind Miller
金额:
$12.43万
依托单位国家:
英国
项目类别:
Fellowship
财政年份:
2019
资助国家:
英国
项目状态:
已结题
起止时间:
2019 至 --

项目摘要

项目成果

相似基金

相关文献

中文摘要
翻译
在此期间,我的目标是发表两篇进一步的研究论文。第一份报告将提供连锁药店和独立药店的价格数据,以及光顾这两种不同药店的顾客的社会经济地位(此前没有发表过关于这一领域的研究)。第二篇论文将汇集来自连锁药店和独立药店的护理质量数据,以提供印度城市环境中药房如何管理儿童腹泻的完整图景。我设立研究金的第二个目标是在全球一级动员支持,为关键病症的管理制定针对特定药品的指导方针。这是我博士提出的一个具体而实用的建议,它强调了儿童腹泻缺乏这样的指导方针。我已经开始与药物使用领域的主要参与者网络以及国际药剂师联合会建立联系,并在推进这一想法方面得到了相当大的支持。其中许多人已经在国家内部担任政策企业家,他们在这些国家有良好的网络和受人尊敬,因此可以帮助塑造这一领域的政策方向。在通过网络和咨询进行进一步的互动之后,我计划领导一份“行动呼吁”文件(在关键个人和组织的支持下),该文件将说明制定此类指导方针的必要性,提出它们可能涵盖的内容,并考虑制定这些指导方针的过程。在攻读博士学位期间,我接受了定量方法的培训,即LSHTM提供的统计学课程,以便进行我的分析。这个奖学金可以让我通过计量经济学的高级培训进一步提高我的定量分析能力。我相信伦敦大学学院的“健康计量经济学”课程会特别提高我作为一名早期职业研究者的技能。最后,我建议利用该奖学金来制定一项资助提案,以研究如何在中低收入国家使用涉及药物控制层次的新监管方法来遏制抗生素的过度使用。抗生素耐药性被广泛认为是全球公众健康的主要威胁。抗生素的使用是导致耐药性的选择压力的主要驱动因素,但这类药物仍然是世界上购买最多的药物之一。在包括药店在内的社区促进抗生素管理已被确定为一个关键的行动领域。对抗菌素耐药性问题进行经济分析,可能会在研究这一日益严重的问题中发挥重要作用,揭示这些动态市场的供应和需求。此外,鉴于与抗生素滥用有关的外部性,改进围绕抗生素提供的有效监管的设计和实施将是至关重要的。这一系列的调查是由我的博士学位的结果引发的:尽管非法销售(通常是不适当的)抗生素在柜台上很普遍,但发现药房工作人员在“H1药物”方面遵循了更好的做法。这是2013年(在印度)引入的一类药物,以应对对抗生素耐药性日益增长的担忧。H1药物清单主要由抗生素(新型和抗结核药物)组成,清单上的药物受到额外的监管控制。在H1药物的情况下,发现药房工作人员受到限制使用此类药物的隐性规范的严格约束。并不是所有的抗生素都是一样的,这是一个重要的观点,对不同的药物使用不同程度的药物控制的潜力还有待探索。监管理论中的新思想,如基于风险和响应的监管,将被用来为这一研究领域提供信息。
英文摘要
During this fellowship, I aim to publish two further research papers. The first will present data on prices of encounters at both chain and independent pharmacies, and the socioeconomic status of customers patronising these two different pharmacy types (no prior research has been published on this area). The second paper will pool quality of care data from both chain and independent pharmacies to provide a complete picture of how childhood diarrhoea is managed at pharmacies in the urban Indian setting.My second objective for the fellowship is to mobilise support at the global level for the creation of pharmacy-specific guidelines for the management of key conditions. This was a specific, practical recommendation from my PhD, which highlighted the lack of such guidelines for childhood diarrhoea. I have already started to develop my contacts with a network of key players in the field of medicine use, and with the International Federation of Pharmacists, and have received considerable support for taking this idea forward. Many of these individuals already serve as policy entrepreneurs within countries, where they are well-networked and respected and thus can help to shape the policy direction of this field. Following further interaction through networking and consultation, I plan to lead on a 'call to action' paper (with the backing of key individuals and organisations), which would state the need for such guidelines, propose what they might cover, and give thought to what the process of producing them would look like.During the course of my PhD I undertook training in quantitative methods, namely statistic courses provided at the LSHTM, in order undertake my analyses. This fellowship would enable me to further improve my quantitative skills through advanced training in econometrics. I believe the UCL 'econometrics for health' course would particularly enhance my skills as an early career researcher. Finally, I propose to use the fellowship to develop a funding proposal in order to investigate how novel regulatory approaches involving hierarchies of drug control may be used in LMICs to curb the overuse of antibiotics. Antibiotic resistance is widely recognised as a leading threat to the public's health, globally. Antibiotic use is a main driver of selection pressure that leads to resistance, yet this class of medicines continue to be amongst the world's most highly purchased. Promoting antibiotic stewardship in the community, encompassing pharmacies, has been identified as a key area for action. Applying an economic analysis lens to the problem of antimicrobial resistance will likely play an important role in the study of this growing problem, shedding light on both supply and demand in these dynamic markets. Further, given the externalities associated with antibiotic misuse, improving both the design and implementation of effective regulation surrounding the provision of antibiotics will be paramount.This line of enquiry was sparked by a result from my PhD: although the illegal sale of (often inappropriate) antibiotics over the counter was widespread, pharmacy staff were found to follow better practice withrespect to 'H1 medicines'. These are a category of medicines that were introduced (in India) in 2013 in response to growing concerns over antibiotic resistance. The H1 medicine list is comprised mainly of antibiotics (novel classes and anti-tuberculosis drugs) and medicines on the list are subject to additional regulatory controls. In the case of H1 medicines, pharmacy staff were found to be tightly bound by implicit norms that restrict the use of such medicines. The idea that not all antibiotics are equal is an important one, and the potential of using different levels of drug control for different medicines is yet to be explored. New thinking in regulatory theory, such as risk-based and response regulation, will be used to inform this area of study.
期刊论文(2)
专著(0)
科研奖励(0)
会议论文
DOI: 10.34172/ijhpm.2020.214
发表时间: 2022-05-01
期刊: INTERNATIONAL JOURNAL OF HEALTH POLICY AND MANAGEMENT
影响因子: 3.5
作者: [Miller, Rosalind, Goodman, Catherine]
通讯作者: Goodman, Catherine
海外基金